Calin Galaseanu, recently appointed general manager of Novo Nordisk Hungary, elaborates on the country’s strong treatment paradigm for diabetes. He goes on to highlight Hungary’s key positioning as a strategic affiliate for Novo Nordisk in the areas of market access success and clinical trial capabilities.
Hungary is actually one of the most fortunate countries in Europe for the treatment of diabetes. These products are well reimbursed, and patients have access to virtually all of the latest innovation that is introduced to the market
